GXNPC1 is a novel autologous adipose-derived stem cell therapy for the treatment of chronic stroke (first-in-class). In pre-clinical research, GXNPC1 has demonstrated that it can increase the expression of homing effect, anti-inflammation and angiogenesis; In animal model of ischemic stroke, GXNPC1 showed improvement by behavior tests, including beam walking, locomotor activity, and rotarod analysis.

According to the human trial phase I, the outcomes demonstrated that there was no adverse event. Moreover, all subjects significantly improved after GXNPC1 tranplantation at 6 months follow-up (Tsung-Lang Chiu et al., 2022). Currently, GXNPC1 is ongoing in clinical trial phase II (NCT04088149).

Discovery Channel Taiwan - A Documentary Film about GXNPC1 Human Trial


SCI Journal


Journal of tissue engineering and regenerative medicine

Jan. 2022

Intracerebral transplantation of autologous adipose-derived stem cells for the treatment of chronic ischemic stroke: A phase I study

Cell Transplantation

Jan. 2016

Therapeutic Effect of Ligustilide-Stimulated Adipose-Derived Stem Cells in a Mouse Thromboembolic Stroke Model

Cell Transplantation

Apr. 2014

Adopting ADSCs for the treatment of chronic stroke

Journal of Neuroscience and Neuroengineering

Feb. 2013

Pre-Clinical Studies and Clinical Application of Adipose-Derived Stem Cells